NCT03048058

Internet Surveys and Their Impact on Adherence for Rosacea

Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.

Detailed description

An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.Subjects will be randomized 1:1 to be in the weekly internet survey group or the standard care non-survey group. At each visit, review of the internet survey use will be done to assess adherence to the medication. . Disease severity measures ((Clinician's Erythema Assessment (CEA), and Lesion counts will be obtained. QOL will be measured.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	brimonidine topical gel 0.33% & survey	The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
DRUG	brimonidine topical gel 0.33% & SOC	All subjects will receive standard-of-care brimonidine topical gel 0.33%

Timeline

• Start date: 2016-05-05
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2017-02-09
• Last updated: 2018-10-10
• Results posted: 2018-08-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study